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Cardiovascular
Summary
Background: Prosthetic valve obstruction is a relatively
rare, but potentially fatal complication in patients with
prosthetic heart valves. The diagnosis and appropriate
management of these patients present a challenge to both
the cardiologist and the cardiac surgeon. Despite efforts
over the last 30 years to prevent this complication, it
remains a lifelong risk. Obstruction is caused by pannus
formation, thrombus formation or a combination of pan-
nus and thrombus. Valve replacement has traditionally
been the treatment of choice.
Methods: Patients were selected from echocardiography
and surgical reports between January 1991 and
February 2001. All patients were analysed with regard to
demographic information, clinical features, imaging
results, treatment and outcome data. INR values on pre-
sentation were obtained from haematology archives.
Results: A total of 32 patients presented on 34 occasions.
There were 25 women and seven men. Obstruction
occurred in the mitral position in 56% of cases and in the
aortic position in 44% of cases. All but two valves were St
Jude bileaflet valves. Patients generally presented with
severe dyspnoea (NYHA class IV in 64.7%) and poor
anticoagulation control (INR < 2.5 in 75.8%). The initial
imaging modality used in all cases was transthoracic
echocardiography. Fluoroscopy was used in five cases
and transesophageal echocardiography in only two cases.
Valve replacement was performed on 20 patients, six
patients received thrombolysis and the remaining eight
patients did not receive any treatment. Outcome was
poor with an overall mortality of 64.7%.
Conclusions: Given the extremely high mortality rate
with current management, the treatment of prosthetic
valve obstruction with thrombolysis in selected patients
deserves consideration in a prospective study.
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Prosthetic valve obstruction is a relatively rare, but poten-
tially fatal complication in patients with prosthetic valves.
The diagnosis and appropriate management of these patients
present a challenge to both the cardiologist and the cardiac
surgeon. Since the introduction of cardiac valve replacement
surgery in 1960 by Dwight Harken from Boston, prosthesis
thrombogenicity remained a constant source of post-opera-
tive morbidity and mortality.1 Efforts over more than three
decades to prevent this problem include the development of
bileaflet valves and less thrombogenic material, improve-
ment of surgical techniques, optimalisation of post-operative
care and long-term anticoagulation. Despite these efforts,
valve obstruction remains a lifelong risk in patients who
have a valve replacement.
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The reported incidence of prosthetic valve obstruction
ranges from 0.2 to 6% in aortic and mitral valves, and as
high as 20% in tricuspid valve prosthesis.2,6 The most com-
monly reported causes for prosthetic valve obstruction in
Europe and the United States are pannus formation with
thrombosis (35–45%), pannus formation only (31–59%) or
thrombosis only (15–24%).2,3 Reports from South Africa and
India suggest an increased incidence of primary thrombus
formation of 54%.4,5
The pathogenesis of intracardiac thrombus formation
occurring with or without the implantation of prosthetic
material is complex.1 It is often the direct result of the throm-
bogenic surface of the prosthesis, altered trans-prosthetic
blood flow or inadequate anticoagulation, but other causes of
hypercoagulability must always be excluded (Table I).
The diagnosis of obstruction is generally based on the
presence of specific clinical, echocardiographic and fluoro-
scopic features. The clinical presentation may be acute, sub-
acute or chronic. Common presenting symptoms and signs
are listed in Table II.4,5,7,8 The most useful imaging modalities
for confirmation of prosthetic valve obstruction include
cinefluoroscopy, transthoracic echocardiography (TTE) and
transoesophageal echocardiography (TEE) (Table III).
Cinefluoroscopy is an excellent method to detect prosthetic
valve dysfunction. It requires minimal expertise and is read-
ily available in tertiary centres. Two-dimensional TTE may
visualise thrombus or decreased valve motion but resolution
is usually poor. Doppler TTE may overestimate increased
transvalvular gradients and underestimate decreased valve
area. Transoesophageal echocardiography has an increased
ability to detect thrombi on mitral prosthesis and in
atria.3,5,6,8–11
It is difficult to diagnose the specific morphological
process responsible for obstruction preoperatively, based 
on the clinical, echocardiographic and fluoroscopic features.
A short duration of symptoms (< 15 days) and poor anti-
coagulation status (INR < 2.5) suggest primary thrombus
formation.12,13 Fluoroscopic evidence of abnormal valve
motion and echocardiographic evidence of increased trans-
valvular gradients confirm a clinical diagnosis of obstruc-
tion, but do not provide any further information concerning
the nature of the obstruction. In a recent publication, Vitale
et al. suggest that incomplete obstruction or abnormal move-
ment of only one leaflet is more in favour of thrombus for-
mation.12 Due to its superior resolution, TEE is widely recog-
nised as the method of choice for diagnosis of the specific
nature of the obstructive process. The impression of
decreased ultrasound intensity, i.e. as soft mass, strongly
suggests a thrombus.13 When a thrombus is seated on a nor-
mal functioning prosthesis it is a strong indication of prima-
ry thrombotic obstruction.9
Appropriate treatment should be started immediately
after diagnosis of the obstruction, the therapeutic goal being
rapid restoration of prosthetic function and elimination of
thrombotic material. Surgery has traditionally been the treat-
ment of choice. This may include either thrombectomy or
valve replacement. Valve replacement is preferable to
thrombectomy because it has a lower incidence of rethrom-
bosis.14 Surgical mortality increased from 2 to 4% in low-risk
patients, to 25 to 40% in high-risk patients. Factors associat-
ed with increased postoperative mortality include valve
prosthesis in the mitral position, severely ill patients, com-
plicated surgery and co-morbid conditions (Table IV).15
Due to high mortality rates in the high-risk group, throm-
bolysis has emerged as an alternative to surgical intervention
in selected patients. It was first described as successful
TABLE I. THE PATHOGENESIS OF PROSTHETIC
VALVE THROMBOSIS
1. Molucular interaction between plasma components and
prosthesis
• adsorption of plasma proteins
• adhesion of molecules
2. Transprosthetic blood flow
• turbulent flow with shear stress and recirculation
downstream
• subclinical haemolysis – release of ADP, PF-4 and
thromboglobulin
3. Inadequate anticoagulation
4. Other pro-thrombotic factors
• loss of atrial contractions
• drugs, e.g. contraceptives
• malignant tumours
• systemic diseases, e.g. SLE
• incomplete endothelialisation of the valve ring
TABLE II. CLINICAL PICTURE OF PROSTHETIC
VALVE THROMBOSIS ON PRESENTATION4,5,7,8
Symptoms Dyspnoea (NYHA class II–IV) 81–97%
Cough 66–73%
Chest pain 24–44%
Embolisation (central/peripheral) 13–19%
Asymptomatic 0–8%
Signs Decreased/absent valve click 56–100%
Atrial fibrillation 20–38%
Pulmonary oedema 26–80%
New/changing murmer 21–26%
Hypotension 21–22%
Cardiac arrest 3–5%
Acute myocardial infarction 2–6%
TABLE III. SPECIAL INVESTIGATION USED FOR
DIAGNOSIS OF VALVE OBSTRUCTION
Cinefluoroscopy Decreased or absent leaflet motion
Decreased or absent opening and closing
angles
Transthoracic 2–D echo: May visualise thrombus or
echocardiography decreased valve motion but resolution is
poor
Doppler: increased transvalvular gradients
may be overestimated
Doppler: decreased valve area may be
underestimated.
Transesophageal Optimal resolution
echocardiography* Increased ability to detect thrombi on
mitral prosthesis and in atria
*Method of choice for diagnosing specific nature of the obstructive
process.
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therapy for right-sided thrombosis by Luluaga et al. in
1971.16 In 1974 Baille et al. reported successful treatment of
left-sided prosthetic thrombosis.17 Success rates with throm-
bolytic therapy in the range of 73 to 86%,18,19 and even 100%
in one series20 have been reported. Complications of throm-
bolytic therapy (Table V) are usually not of catastrophic
nature and can be limited by careful patient selection.3,9,17–20
Systemic embolism, however, remains a concern with
figures of up to 22% reported in the USA and Europe.1,6,17,18
Lower rates of embolism (12%) have been reported from
India.17,18
The choice of thrombolytic agent (streptokinase, uroki-
nase or t-PA) does not seem to have any influence on the
success rate, although thrombolysis may be more rapid and
duration of treatment shorter if t-PA is used.1 Fibrinolysis in
selected patients has also been reported to be more cost-
effective than surgery.4,19–21 Some authors have proposed spe-
cific indications for thrombolytic therapy.9,12 Patients with
reasonable proof of primary thrombus formation, right-sided
prosthetic valve thrombosis, and co-morbid conditions with
a high surgical risk are ideal candidates for thromboly-
sis.2,6,9,12,17,18 Conflicting ideas exist on the appropriate man-
agement of the severely compromised patient. Although
these patients have a high surgical risk, time lost waiting for
thrombolytic therapy to be effective may also be fatal.
Objective
Our aim is to document our experience of the diagnosis and
management of prosthetic valve obstruction at Tygerberg
Hospital between January 1991 and February 2001. This
study is the first of its kind to be conducted at Tygerberg
Hospital and the data may provide us with a platform to
direct further prospective research in the field.
Study design
This is a retrospective, descriptive study of all the patients
presenting at Tygerberg Hospital between January 1991 and
February 2001, with a final diagnosis of prosthetic heart
valve obstruction.
Methods
All the echocardiography reports between January 1991 and
February 2001 were systematically reviewed for patients
with a confirmed diagnosis of prosthetic valve obstruction.
Surgical reports of prosthetic valve re-operation over the
same period were also screened for patients with a diagnosis
of valve obstruction.
Folders and microfilms of the relevant patients were
obtained from hospital records.
The following data were gathered from the clinical notes,
post-operative reports and imaging reports:
Demographic information: Age, gender, position of 
clotted valve(s), and type of valve.
Clinical presentation: Interval between valve surgery and
presentation, type and duration of symptoms, compliance
with anticoagulation, findings on physical examination, and
co-morbid conditions.
Special investigations: ECG changes, chest X-ray reports,
and INR results of relevant patients were obtained from the
haematology archives (adequate anticoagulation was defined
as an INR value of > 2.522).
Imaging: Fluoroscopy – leaflet motion
Echocardiography – position and size of valve(s)
– transvalvular gradients
(adjusted for valve size)
– leaflet motion
– pulmonary hypertension
– ejection fraction
– nature of obstructive process.
Treatment and outcome: Surgery or thrombolysis, time from
presentation to treatment, complications, and duration of
hospital stay.
Results
Clinical presentation
Between January 1991 and February 2001, 32 patients
presented on 34 occasions with left-sided valve obstruc-
tion. This included seven men and 25 women, with a 
mean age of 36 years (range: 17.9–62.9 years). Thirty
patients had their initial valve replacement performed at
Tygerberg Hospital. Eleven patients received double valve
replacement.
The interval between implantation and obstruction of 
the prosthetic valve ranged from 45 days to 188 months
(mean: 67 months). The mean time from the onset of
symptoms to presentation was 6 days (range: 1–30 days).
Obstruction occurred in the mitral position in 19 patients
(56%) and in the aortic position in 15 patients (44%). 
With the exception of two patients, all cases had bileaflet
prosthetic valves (St Jude Medical). One patient had a 
Björk-Shiley tilting-disc valve and one patient a Carpentier-
Edwards bioprosthesis.
The symptoms and signs of all patients on presentation
are listed in Table VI. Twenty-two patients presented in
New-York Heart Association functional class IV; nine of
them being in shock, three were in class III and four in 
TABLE IV. FACTORS ASSOCIATED WITH
INCREASED POST-OP MORTALITY15,16
Mitral valve position
NYHA class IV symptoms
Emergency surgery
Need for multiple procedures
Long cross-clamp times
Associated non-cardiac surgical risks
TABLE V. COMPLICATIONS OF THROMBOLYTIC
THERAPY3,9,15,18,19,20,21
Thrombo-embolism 8–22%
Bleeding 5–25%
Allergic reaction/anaphylaxis 0–4%
Re-thrombosis 12–40%
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class II (Fig. 1). Five patients denied any symptomatology.
In two patients, the diagnosis was suspected on clinical
grounds due to sinus tachycardia, an absent prosthetic 
click and a changing murmur. The remaining three asympto-
matic patients were diagnosed on routine follow-up trans-
thoracic echocardiography. Chest pain was a presenting
complaint in 17 cases (50%). Seven patients had typical
angina pectoris. Although cough is mentioned in the litera-
ture as a prominent presenting complaint (see Table II), we
could not find consistent documentation of its presence or
absence. In view of the high percentage of patients present-
ing with pulmonary oedema though, one would expect it to
be a prominent and early symptom of prosthetic valve
obstruction.
Co-morbid conditions included SLE with nephrotic
syndrome (1), diabetes mellitus (2), coronary artery disease
(7), pneumonia (3), gout (1), sero-negative arthritis (1),
pregnancy (1), haemoptysis (1) and one patient who tested
positive for HIV. Four patients presented with a thrombo-
embolic event; two had cerebral emboli and two presented
with acute myocardial infarction, presumed to be of embol-
ic nature. One patient had an embolism to his right leg 
while waiting for re-operation. The majority of the patients
(82%) were in sinus rhythm. Of the six patients in atrial
fibrillation, only one presented with a thrombo-embolic
event. An absent prosthetic click was reported in 50% of
cases. Almost all the patients (31), including one asympto-
matic patient, had basal crepitations on auscultation of 
the lungs.
Special investigations
Anticoagulation was considered inadequate (INR < 2.5) in
75.8% of the admissions (Fig. 2). Anticoagulant administration
was discontinued before presentation on six occasions (18%).
Chest X-rays showed evidence of pulmonary oedema in
29 cases. ECG abnormalities included sinus tachycardia, 1st
degree AV-block, atrial fibrillation, bi-atrial enlargement, left
ventricular hypertrophy, left and right bundle branch block
and myocardial infarction changes. Two ECGs were report-
ed as normal.
Transthoracic echocardiography was performed in 33 of
the 34 cases. Abnormal leaflet motion was observed in all
but one patient. Pressure gradients, as measured by doppler
echocardiography on presentation, were increased in all
cases. Serial measurements were only available in five
patients and did not show a gradual increase in gradients
over the time before the obstruction. Echocardiographic evi-
dence of pulmonary hypertension was reported in 25 cases
(74%); two asymptomatic patients had increased pulmonary
pressures. On transthoracic echocardiography, thrombus was
suspected in 20 patients and pannus formation in one patient.
No comment was made on the presence of thrombus or pan-
nus in the remaining 13 cases. Primary thrombus formation
was wrongly suspected in three cases and the patient pro-
posed to have pannus formation turned out to have a combi-
nation of pannus and thrombus.
Cinefluoroscopic examination was utilised on only five
occasions. All the patients had abnormal leaflet motion. One
of these patients had normal leaflet motion reported on
transthoracic echocardiography.
Diagnostic transoesophageal echocardiography was per-
formed on only two occasions. The nature of the obstruction
was correctly diagnosed in both patients – pannus in one
case, and thrombus in the other.
Treatment
Treatment options included valve replacement surgery (20),
thrombolysis (6) or no treatment (8). The interval from hos-
pital admission to treatment varied from 3 hours to 18 weeks
(Table VII). This interval depended mainly on the patients’
condition on presentation and the time necessary to establish
the diagnosis.
TABLE VI. CLINICAL PRESENTATION OF
PROSTHETIC VALVE THROMBOSIS AT TYGERBERG
HOSPITAL BETWEEN JANUARY 1991 AND
FEBRUARY 2001 (34 ADMISSIONS OF 32 PATIENTS)
Symptoms Dyspnoea (NYHA class III–IV) 74%
Chest pain 50%
Embolisation (cerebral/limb) 12%
Asymptomatic 15%
Dyspnoea (NYHA class II) 12%
Signs Pulmonary oedema 91%
Decreased/absent valve click 50%
Abnormal murmur 29%
Hypotension 26%
Atrial fibrillation 18%
Acute myocardial infarction 6%
Fig. 1. Severity of dyspnoea on presentation.
Fig. 2. Anticoagulation status on presentation (available
in 33 of 34 admissions).
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Twenty patients (59%) underwent prosthetic valve
replacement consisting of St Jude bileaflet mechanical pros-
thesis. Reasons for obstruction, reported by the surgeon on
macroscopic examination of the explanted valves included
thrombus only (55%), pannus only (15%) or a combination
of thrombus and pannus (30%). Complications occurred in
50% of cases. Intra-operative acute heart failure and cardiac
arrest was the cause of death in four patients. Post-operative
complications included pneumonia (2), septicaemia (2),
transient acute renal failure (2) and one patient needed evac-
uation of an intrathoracic haematoma. Eleven patients died
(55%); 10 of these patients presented in NYHA class IV. In
the group that survived surgery, only one patient presented in
NYHA class IV.
A total of six patients (17.6%) received thrombolytic treat-
ment. Four patients were considered too ill for surgery. In one
patient who tested HIV positive, the surgeons declined to
offer re-operation. In another case, surgery was not available
due to a lack of postoperative ICU beds. Three patients (50%)
had complications associated with the thrombolytic treat-
ment. One had transient epistaxis, one had upper gastro-
intestinal bleeding and a stroke, and one re-obstructed after
two months. The patient who re-obstructed turned out to have
primary pannus formation on re-operation. Four patients in
the thrombolytic group died (66.6%), including the patient
turned down for surgery due to an ICU bed shortage. This
was also the only patient in the thrombolytic group whose
death could at least partially be contributed to the complica-
tions of thrombolytic treatment (GIT bleed and stroke).
Eight patients (23.5%) did not receive either of the above
treatments. Four of these patients died before emergency
surgery could be carried out; three were not considered for
either treatment due to severe haemoptysis, a large stroke,
and chronic renal failure, respectively. The only survivor in
the group recovered after embolisation of the obstructing
thrombus to his right leg.
Discussion
The incidence of left-sided prosthetic valve thrombosis is
reported in the current literature to be between 0.5 and 6%
per patient year. Although relatively rare, it remains the most
frequent valve-related complication of mechanical prosthe-
ses.3 This study included only patients who presented to
Tygerberg Hospital with obstructed prosthetic valves. We
have no knowledge of the non-presenters, and included in
the study two patients who received their valves at other
institutions. We therefore cannot comment on the incidence
of prosthetic valve obstruction at Tygerberg Hospital during
the last 10 years.
The clinical characteristics of prosthetic valve thrombosis
have been well described by other investigators. Classically
the patient’s condition deteriorates rapidly to become life
threatening in a short period of time. Some patients, howev-
er, may present in a sub-acute, slowly progressive manner. In
another group of patients, usually with non-obstructive
thrombosis, presentation may be insidious or limited to
peripheral embolism.
Kontos et al. evaluated 27 patients presenting to the
Mayo Clinic with prosthetic valve thrombosis over a 19-year
period, and reported that 70% of patients had clinical evi-
dence of prosthetic valve malfunction for 1 week to 6
months prior to presentation.8 In our study, most patients
(66%) presented with a history of onset of symptoms of 1
week or less before presentation. A short duration of symp-
toms may suggest thrombus formation. In this series though,
there was no statistical association between the duration of
symptoms and the pathological process causing obstruction.
A careful and detailed history should always be taken from
patients with prosthetic valves. Even relatively minor symp-
toms should prompt a more intensive search for prosthetic
valve malfunction in an attempt to diagnose these patients
earlier. The most prominent symptoms were dyspnoea and
chest pain. The majority of patients presenting to our unit
already had severe disability. Of the 25 patients in NYHA
class III and IV, only four survived. When complicated by
cardiac shock, the mortality was 100% (Fig. 3).
Chest pain was a common complaint. Although a rela-
tively high percentage of patients (21%) had a history of
underlying coronary artery disease, only one patient in this
subgroup complained of chest pain. The reasons why
patients develop atypical chest pains with prosthetic valve
obstruction are unclear.
Co-morbid conditions that may have contributed to
thrombus formation were present in 12 patients and includ-
ed atrial fibrillation (6), previous myocardial infarction (6),
nephrotic syndrome (1), SLE (1), pregnancy (1) and type 2
diabetes mellitus (2). The only case in this series with
obstruction of a bioprosthesis was due to a combination of
pannus and thrombus formation. Because the Carpentier-
Edwards bioprosthesis is non-thrombogenic, the presence of
atrial fibrillation and an atrial size of 71 mm must have made
a major contribution to thrombus formation in this case. An
important finding was the absence of a prosthetic click on
auscultation in 50% of cases. This supports the 56% report-
ed by Kontos et al.8 Most other studies reported the absence
of prosthetic clicks in up to 100% of patients.4,5,7 Although
TABLE VII. INTERVAL FROM HOSPITAL ADMISSION
TO TREATMENT
Interval No. of patients
< 24 hours 13 (50%)
1 day – 1 week 6 (23%)
1 week – 1 month 5 (19%)
> 1 month 2 (8%)
Fig. 3. Relationship between mortality and presenting
status.
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the presence of an abnormal murmur and basal crepitations
on auscultation are non-specific findings, it should be
sought, and when present investigated appropriately.
Chest X-ray and EGG findings were non-specific, con-
firmed clinical findings only and did not contribute addi-
tional diagnostic or prognostic information.
The anticoagulation status of our patients was generally
suboptimal (Fig. 2), suggesting that sub-therapeutic INR lev-
els contribute to thrombosis of the prosthetic valve. Because
we do not know the INR values of the non-presenters, the
data cannot be analysed to statistically express the risk fac-
tor associated with a sub-therapeutic INR. One must also
keep in mind that a single INR value on presentation does
not reflect the patient’s anticoagulation status during the
weeks or months prior to presentation. It is therefore very
important to keep the INR values within the therapeutic
range at all times. This may be achieved by regular follow-
up, preferably at a dedicated clinic.
Transthoracic echocardiography proved to be adequate in
confirming abnormal or absent leaflet motion in all but one
patient. Although increased transvalvular pressure gradients
were present in all patients, it is of less value as a single mea-
surement due to overestimation of the net pressure gradient
across bileaflet prosthetic valves. Serial measurements with
progressively increasing gradients are more specific.
The major advantage of using transoesophageal echocar-
diography in prosthetic valve obstruction lies in its superior
resolution. More accurate diagnosis of the nature of the
obstruction may prove to be invaluable in cases where
thrombolytic treatment is considered.
Cinefluoroscopic examination was utilised only five
times, and was diagnostic in all cases. The one case in our
study with an increased pressure gradient across the mitral
valve, but with apparently normal leaflet motion on trans-
thoracic echocardiographic examination, was correctly diag-
nosed with cinefluoroscopy, which is an excellent method to
show abnormal leaflet motion, is non-invasive, easy to per-
form and readily available in many hospitals. It may also be
of great value when echocardiographic services are not
immediately available, i.e. after hours or in a peripheral hos-
pital setting.
Currently all the patients presenting at our unit with
prosthetic valve obstruction are considered for re-operation
as the first choice of treatment. In this series, only 59% even-
tually received surgery. The main reason for not receiving
surgery was that the patients were too ill (11 out of 14). 
Four patients in this group received streptokinase and four
died before receiving any treatment. The remaining three
patients were not considered for any treatment due to severe
haemoptysis, a large cerebral infarct, and advanced chronic
renal failure, respectively. Only one patient in the strepto-
kinase group survived but re-obstructed two months later.
With subsequent surgery, pannus formation was reported as
the reason for failure of thrombolysis. Other reasons cited for
not performing surgery included positive HIV status (1) and
a lack of post-operative intensive-care beds (1). Both of these
patients received streptokinase. Only the HIV-positive patient
survived. The only survivor in the group of patients who did
not receive any treatment had embolisation of the obstruct-
ing thrombus to the right leg while awaiting surgery. Follow-
up echocardiography confirmed resolution of the thrombus.
The fact that only six patients were treated with four dif-
ferent regimes of streptokinase probably reflects the lack of
clear guidelines on selecting patients for thrombolysis and
limited experience with this treatment modality. Commonly
recommended treatment regimes include streptokinase 
250 000 U loading dose over 30 minutes, followed by an
infusion of 100 000 U/hr, or tissue plasminogen activator 
(t-PA) 10 mg as a bolus, followed by an infusion of 5 mg/hr.
When full valve mobility is achieved, thrombolytic therapy
may be stopped. All patients should receive an intra-venous
heparin infusion at a rate of 1 000 U/hr after thrombolysis
for a variable period until adequate anticoagulation is
achieved with warfarin.19–21
Intra-operative macroscopic examination of the explant-
ed prosthetic valves showed a clear predominance of prima-
ry thrombus formation and only a small number of patients
with pannus formation. These results contradict several well-
performed studies from Europe and the USA which cited
pannus formation as the most frequent cause of obstruc-
tion.2,3 Our results though, are very similar to other studies
from the developing world.4,5 One reason for the difference
may be a higher rate of inadequate anticoagulation in devel-
oping countries, due mainly to socio-economic factors.
Other reasons may be the different ways of diagnosing the
process, i.e. macroscopic versus microscopic examination,
and differences in study designs.
Overall mortality of patients presenting to our unit with
prosthetic valve obstruction was 64.7%. This extremely high
mortality rate does not compare well with most studies quot-
ed in the literature. The main reason for our high mortality
rate appears to be the poor condition of patients on presenta-
tion to the unit, therefore requiring emergency surgery, the
large number of patients not receiving any form of treatment,
and the lack of criteria to decide on the most appropriate form
of treatment, i.e. valve replacement or thrombolysis.
Although the study was not designed to identify specific risk
factors for mortality, cardiogenic shock and NYHA class IV
on presentation were clearly associated with a poor progno-
sis. Other important factors, which we were unable to inves-
tigate in more detail during this study, and that may have con-
tributed to the high mortality include: time between presenta-
tion and surgery, time to make definitive diagnosis, cross-
clamp times, surgical techniques, experience of the surgeon
and specific post-operative care factors. It is well document-
ed that optimalisation of these factors improves outcome.
We believe the best way to prevent prosthetic valve
thrombosis is to keep the INR within the therapeutic range
and avoid periods of inadequate anticoagulation. Careful
selection of patients for valve replacement by a team includ-
ing a cardiologist, a cardio-thoracic surgeon and a social
worker also plays a major role.
It is likely that earlier diagnosis of prosthetic valve mal-
function may improve prognosis significantly. Taking a good
history and examining the patient thoroughly with every fol-
low-up visit is mandatory. The use of cinefluoroscopy may
speed up the diagnostic process and facilitate earlier treat-
ment. Transoesophageal echocardiography is the imaging
modality of choice for diagnosing thrombus or pannus for-
mation.
From this study it appears that thrombolysis as a treat-
ment modality is under-utilised, possibly due to a lack of
guidelines for selecting suitable candidates (Fig. 4).
Thrombolytic therapy may prove to be particularly benefi-
cial in patients considered to have high non-cardiac surgical
risks and in patients presenting with NYHA class IV symp-
toms or cardiogenic shock. Primary thrombus formation was
the predominant cause of prosthetic valve obstruction at
Tygerberg Hospital during the last 10 years and a large num-
ber of patients were poor candidates for surgery. Given these
factors and the very high mortality rate with the current man-
agement of prosthetic valve obstruction, treatment with
thrombolysis in selected patients deserves consideration in a
prospective study.
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Fig. 4. Proposed algorithm for the management of prosthetic valve obstruction.
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